Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis

Authors:

Abstract
The pro-inflammatory cytokine interleukin (IL)-17A plays a pivotal role in psoriasis pathogenesis. Secukinumab, a fully human monoclonal antibody (mAb) that selectively targets IL-17A, has been demonstrated to be highly efficacious for treatment of moderate to severe psoriasis, starting at early time points, with a sustained effect and a favourable safety profile. mAb therapies may be associated with production of antidrug antibodies (ADA) that can affect drug pharmacokinetics, diminish response, or cause hypersensitivity reactions. To investigate the immunogenicity of secukinumab across six phase 3 clinical trials of plaque psoriasis subjects treated with secukinumab for up to 52 weeks and an additional follow-up time point at Week 60. Immunogenicity in plaque psoriasis subjects exposed to secukinumab was evaluated at Baseline and at Weeks 12, 24, 52 and 60. Treatment-emergent ADA (TE-ADA) were defined as a positive ADA signal detected in post-treatment samples from subjects with a negative Baseline signal. Confirmed positive samples were further analysed for drug-neutralising potential. Among 2,842 subjects receiving secukinumab and evaluated for ADA, 11 (0.4%) developed TE-ADA. Associations between TE-ADA and secukinumab dose, frequency, or mode of administration were not observed. Neutralising antibodies were detected in three of nine evaluable subjects with TE-ADA. Secukinumab immunogenicity was low as demonstrated by evidence that TE-ADA were detected in 11 of 2,842 (0.4%) moderate to severe plaque psoriasis subjects treated with secukinumab. All but one of the subjects with TE-ADA were biologics naïve. Neither TE-ADA nor neutralising antibodies were associated with loss of secukinumab efficacy or issues of clinical concern.
Funding Information
  • Novartis Pharma

This publication has 29 references indexed in Scilit: